

ENZO BIOCHEM INC
Form 8-K
January 06, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **January 6, 2016**

Enzo Biochem, Inc.

(Exact Name of Registrant as Specified in Its Charter)

New York

(State or Other Jurisdiction of Incorporation)

001-09974

13-2866202

(Commission File Number) (IRS Employer Identification No.)

527 Madison Avenue

Item 8.01 Other events

On January 6, Enzo Biochem, Inc. (the “Company”) issued a press release of corporate development updates at its annual shareholders meeting held today, including the details of its strategic plan for growing proprietary molecular diagnostics platforms and assays, the patent infringement settlement with Agilent Technologies, and the re-election of its director nominees.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of Enzo Biochem, Inc., dated January 6, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: January 6, 2016 By: /s/ Barry W. Weiner
Barry W. Weiner
President